Miles Prince Q&A Update
Prescient Therapeutics: Q&A Update with Professor H. Miles Prince Reach Markets recently interviewed Professor H....
Prescient Therapeutics: Q&A Update with Professor H. Miles Prince Reach Markets recently interviewed Professor H....
Prescient Therapeutics, an ASX-listed company, is engaged in the development of drugs targeting various forms...
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) CEO and managing director Steven Yatomi-Clarke sits down with Jonathan...
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) CEO and managing director Steven Yatomi-Clarke sits down with Jonathan Jackson...
Prescient Therapeutics: Investor Briefing with CEO and Managing Director, Steven Yatomi-Clarke CEO and Managing Director,...
Pitt Street Research Briefing on Prescient Therapeutics (ASX: PTX) Reach Markets interviewed Co-Founder and Senior...
Prescient Therapeutics: PTX-100 targeted cell therapy briefing Prescient Therapeutics CEO and MD Steven Yatomi-Clarke gave...
Prescient Therapeutics: Investor Briefing with CEO and Managing Director, Steven Yatomi-Clarke CEO and Managing Director,...
Prescient Therapeutics (ASX: PTX) had a solid FY23 that has set the stage for a...
Steven Yatomi-Clarke, CEO and MD of Prescient Therapeutics (ASX: PTX) recently presented at the TechKnow...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.